Free Trial

CEL-SCI (CVM) Competitors

CEL-SCI logo
$9.45 +1.27 (+15.53%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$9.29 -0.16 (-1.69%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVM vs. LFVN, IMAB, BDTX, BIOA, PBYI, NVCT, CCCC, ACOG, ENTA, and MOLN

Should you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Lifevantage (LFVN), I-Mab (IMAB), Black Diamond Therapeutics (BDTX), BioAge Labs (BIOA), Puma Biotechnology (PBYI), Nuvectis Pharma (NVCT), C4 Therapeutics (CCCC), Alpha Cognition (ACOG), Enanta Pharmaceuticals (ENTA), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry.

CEL-SCI vs. Its Competitors

Lifevantage (NASDAQ:LFVN) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, CEL-SCI had 5 more articles in the media than Lifevantage. MarketBeat recorded 5 mentions for CEL-SCI and 0 mentions for Lifevantage. CEL-SCI's average media sentiment score of 1.08 beat Lifevantage's score of 0.00 indicating that CEL-SCI is being referred to more favorably in the news media.

Company Overall Sentiment
Lifevantage Neutral
CEL-SCI Positive

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 12.1% of CEL-SCI shares are owned by institutional investors. 20.7% of Lifevantage shares are owned by insiders. Comparatively, 9.9% of CEL-SCI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lifevantage has a net margin of 4.12% compared to CEL-SCI's net margin of 0.00%. Lifevantage's return on equity of 34.67% beat CEL-SCI's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifevantage4.12% 34.67% 15.24%
CEL-SCI N/A -238.05%-104.65%

Lifevantage presently has a consensus price target of $30.50, indicating a potential upside of 142.45%. Given Lifevantage's stronger consensus rating and higher probable upside, research analysts clearly believe Lifevantage is more favorable than CEL-SCI.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifevantage
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
CEL-SCI
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Lifevantage has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Lifevantage has higher revenue and earnings than CEL-SCI. CEL-SCI is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifevantage$200.16M0.79$2.94M$0.6918.23
CEL-SCIN/AN/A-$26.92M-$12.61-0.75

Summary

Lifevantage beats CEL-SCI on 13 of the 15 factors compared between the two stocks.

Get CEL-SCI News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVM vs. The Competition

MetricCEL-SCIBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$50.28M$267.92M$5.49B$20.65B
Dividend YieldN/AN/A4.73%3.67%
P/E Ratio-19.69N/A28.7829.03
Price / SalesN/A327.48372.2066.13
Price / CashN/A22.4435.4522.84
Price / Book63.0010.418.274.43
Net Income-$26.92M-$106.40M$3.25B$994.22M
7 Day Performance15.24%-7.85%-3.70%-3.39%
1 Month Performance275.00%18.32%4.34%-2.09%
1 Year Performance-72.37%6.03%25.90%10.09%

CEL-SCI Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVM
CEL-SCI
1.2111 of 5 stars
$9.45
+15.5%
N/A-72.6%$50.28MN/A-19.6943Positive News
Short Interest ↑
LFVN
Lifevantage
3.8043 of 5 stars
$13.13
-4.2%
$30.50
+132.3%
+55.9%$172.58M$200.16M19.03260
IMAB
I-Mab
2.514 of 5 stars
$1.87
-11.4%
$6.00
+220.9%
+100.0%$172.30MN/A0.00380News Coverage
Gap Up
High Trading Volume
BDTX
Black Diamond Therapeutics
2.3023 of 5 stars
$2.93
-1.3%
$12.80
+336.9%
-57.3%$168.88M$70M48.8390Positive News
Upcoming Earnings
Gap Down
BIOA
BioAge Labs
N/A$4.53
-1.9%
N/AN/A$165.63MN/A0.00N/APositive News
PBYI
Puma Biotechnology
3.6469 of 5 stars
$3.34
+1.8%
$7.00
+109.6%
-12.3%$162.79M$230.50M4.34200Upcoming Earnings
NVCT
Nuvectis Pharma
2.3816 of 5 stars
$7.60
-2.3%
$17.00
+123.7%
+10.0%$162.55MN/A-6.738News Coverage
Upcoming Earnings
Analyst Revision
CCCC
C4 Therapeutics
2.3831 of 5 stars
$2.18
-3.5%
$12.00
+450.5%
-68.3%$160.48M$35.58M-1.48150News Coverage
Positive News
ACOG
Alpha Cognition
1.2242 of 5 stars
$9.73
-2.4%
$20.00
+105.5%
N/A$159.72MN/A-8.11N/APositive News
ENTA
Enanta Pharmaceuticals
3.7048 of 5 stars
$8.03
+8.5%
$18.50
+130.4%
-52.0%$158.19M$67.64M-1.77160News Coverage
Upcoming Earnings
Analyst Revision
Gap Up
MOLN
Molecular Partners
2.172 of 5 stars
$3.88
+0.3%
$12.00
+209.3%
-55.9%$156.19M$5.65M-2.02180Gap Down

Related Companies and Tools


This page (NYSE:CVM) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners